title: [Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids].
abstract: BACKGROUND
  The relationships between selected steroids, SHBG, growth hormone, IGF-1, IGF BP-3 and indicators of glucose metabolism were studied in the group of 20 female patients (15-20 yrs) on long-term treatment with low prednisone doses (< 0.3 mg/kg/day) (baseline phase) and after adding 1000 mg of metformin per day for following 6 months to improve impaired glucose metabolism (control phase).
  
  
  RESULTS
  Lower basal DHEAS and DHEA (DHEA/S) levels were found as compared with reference values. Only DHEAS level returned into the reference range after the treatment with metformin. Decrease of DHEA/S depended on the doses (DHEAS -0.7621, DHEA -0.7685). Positive correlations between DHEA/S and of the results insulin tolerance were found as at the baseline (+0.4452, resp. +0.4455) as well as in the control period after the metformin administration (+0.7549, resp. +0.6073). Testosterone (T) and dihydrotestosterone(DHT) values were within the reference range during the whole study. Due to very low SHBG levels higher free androgen index (FAI) was recorded in more than half of the patients. Significant relationships were revealed between former gonadal androgens and indicators of glucose metabolism deterioration at the control phase: T correlated: with fasting insulin (+0.6005), with HOMAIR (+0.5380), with insulin/glucose (+0.5261), with fasting glucose (+0.9268), with AUC glucose (+0.6792), FAI: with fasting insulin (+0.5560), with HOMAIR (+0.5269), with fasting glucose (+0.9025), with AUC glucose (+0.7143), DHT: with fasting C peptide (+0.7921), with AUC C peptide (+0.7143). SHBG correlated: with fasting glucose (-0.6519), and with AUC glucose (-0.5868). The tendency of GH to lower, and IGF-1, IGF BP-3 to higher values at the baseline changed at the control phase: fasting and AUC value of GH increased (signif.), while were IGF-1 (nonsignif.) and IGF BP-3 (signif.) levels decreased. Surprisingly, no correlation was observed between GH and parameters of glucose metabolism. Contrary to GH, baseline IGFBP-3 values correlated: with HOMAIR (+0.5002), with insulin/glucose (+0.4860). The same relationships were found between AUC IGF BP-3 (+0.5676, +0.5559), IGF-1 (HOMAIR only +0.5412), IGF-1/IGF BP-3 (+0.5059, +0.5716) and parameters of insulin sensitivity (HOMAIR, insulin/glucose) in the control period. For the first time negative correlations between IGF-1, IGF-1 AUC, IGF BP-3, IGF-1/IGF BP-3 and somatostatin blood levels were discovered at the control phase.
  
  
  CONCLUSIONS
  The study brought a number of new information about the importance of the "non-classical" glucoregulatory hormones in impairment of glucose metabolism, during long-term administration of low prednisone doses. The results suggest, that without normalisation of low DHEA/S, SHBG and high FAI levels it would not be possible to correct glucose metabolism properly in patients with long-term glucocorticoid therapy.
authors.affiliation: Endokrinologický ústav, Praha. kvondra@endo.cz
authors.forename: K
authors.initials: K
authors.lastname: Vondra
authors.forename: R
authors.initials: R
authors.lastname: Hampl
authors.forename: D
authors.initials: D
authors.lastname: Nĕmcová
authors.forename: M
authors.initials: M
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Hoza
authors.forename: A
authors.initials: A
authors.lastname: Kot'átková
authors.forename: L
authors.initials: L
authors.lastname: Stárka
authors.forename: J
authors.initials: J
authors.lastname: Vrbíková
authors.forename: V
authors.initials: V
authors.lastname: Zamrazil
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood; D003240:Connective Tissue Diseases / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D005947:Glucose / Q000378:metabolism*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000032:analysis*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008687:Metformin / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D012738:Sex Hormone-Binding Globulin / Q000032:analysis*
chemical_list: D000728:Androgens; D005938:Glucocorticoids; D007004:Hypoglycemic Agents; D007328:Insulin; D018972:Insulin-Like Growth Factor Binding Protein 3; D012738:Sex Hormone-Binding Globulin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D008687:Metformin; D005947:Glucose; D011241:Prednisone; D006854:Hydrocortisone
vernacular_title: Vztah nĕkterých steroidů, SHBG, IGF-1, IGF BP-3 a růstového hormonu k poruchám glycidového metabolizmu pri dlouhodobé lécbĕ nízkými dávkami glukokortikoidů.